Last reviewed · How we verify

Mitoxantrone, Cytarabine — Competitive Intelligence Brief

Mitoxantrone, Cytarabine (Mitoxantrone, Cytarabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (topoisomerase II inhibitor + nucleoside analog). Area: Oncology.

marketed Chemotherapy combination (topoisomerase II inhibitor + nucleoside analog) Topoisomerase II (mitoxantrone); DNA polymerase (cytarabine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Mitoxantrone, Cytarabine (Mitoxantrone, Cytarabine) — The First Hospital of Jilin University. Mitoxantrone and cytarabine are chemotherapy agents that work together to inhibit DNA synthesis and induce apoptosis in leukemic cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mitoxantrone, Cytarabine TARGET Mitoxantrone, Cytarabine The First Hospital of Jilin University marketed Chemotherapy combination (topoisomerase II inhibitor + nucleoside analog) Topoisomerase II (mitoxantrone); DNA polymerase (cytarabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (topoisomerase II inhibitor + nucleoside analog) class)

  1. The First Hospital of Jilin University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mitoxantrone, Cytarabine — Competitive Intelligence Brief. https://druglandscape.com/ci/mitoxantrone-cytarabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: